The Egyptian Drug Authority confirms that the domestic pharmaceutical market is stable due to precise monitoring and proactive measures taken against global supply chain shifts.
Ali El-Ghamrawy, the Chairman of the EDA, said that the state supports local medicine availability and boosts exports to open new markets for Egyptian medical products. He emphasized the commitment to overcoming regulatory obstacles and developing oversight systems according to international standards to enhance global trust in Egyptian drugs.
Yassin Ragai, the Assistant Chairman of the EDA, pointed out that the strategic stock for essential medicines and biological preparations covers up to six months for most products. This includes treatments for blood pressure and diabetes as well as heart diseases, oncology, and complex biologicals.
Approximately 55 percent of the required raw materials for the current year have already been imported while local stocks cover the majority of consumer needs.
The assistant chairman added that 80 percent of active ingredients in the market have a stock sufficient for more than three months of production. He confirmed that the local manufacturing rate has reached 91 percent for necessary medicines, which reduces reliance on imports and increases market resilience.
The authority monitors pharmaceutical shipments daily to ensure the continuity of supply chains and the availability of raw materials in coordination with all companies.
The report noted that pharmaceutical exports grew to reach 147 countries with a total value of $1.3 billion in 2025 reflecting a growth rate of over 20 percent.
Source: Egypt Today
